Acurx reports preclinical DNA Pol IIIC inhibitors spare gut microbiome while reducing MRSA in mice
Acurx Pharmaceuticals announced that its preclinical DNA polymerase IIIC inhibitor candidates demonstrated antibacterial activity against MRSA in a mouse thigh infection model and preserved gut microbial diversity, unlike the comparator linezolid. The study, published in ASM Microbiology Spectrum, showed the compounds maintained anaerobic bacterial populations and metabolic pathways. The company highlighted that these candidates qualify for FDA QIDP and Fast‑Track designations and are aimed at serious Gram‑positive infections. Acurx also noted the enrollment of the first patient in the PATHFINDER trial for ibezapolstat in recurrent C. difficile infection.
Why it matters
The data suggest Acurx’s pipeline may offer a narrower‑spectrum antibiotic with reduced risk of gut dysbiosis, which could be attractive to clinicians and payors. The FDA designations may accelerate regulatory review, potentially bringing these agents to market faster.
Key facts
- 1The study compared three new oral Pol IIIC inhibitor candidates with linezolid in a neutropenic mouse thigh infection model and found all three reduced MRSA bacterial burden. prnewswire.com
- 2The Pol IIIC inhibitors preserved high gut microbial diversity and metabolic function, whereas linezolid caused marked disruption. prnewswire.com
- 3The compounds specifically maintained anaerobic microbiome components while linezolid depleted them. prnewswire.com
- 4Acurx’s preclinical candidates are eligible for FDA QIDP and Fast‑Track designations. prnewswire.com
- 5The company enrolled its first patient in September in the PATHFINDER trial evaluating ibezapolstat in about 20 patients with multiply‑recurrent C. difficile infection. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.